CORRECTING and REPLACING Pinteon Therapeutics Encouraged by Publication of Preclinical Study Supporting PNT001 for the Treatment of Tauopathies in Science Translational Medicine

NEWTON, Mass.–(BUSINESS WIRE)–Please replace the release with the following corrected version due to multiple revisions.

The updated release reads:

PINTEON THERAPEUTICS ENCOURAGED BY PUBLICATION OF PRECLINICAL STUDY SUPPORTING PNT001 FOR THE TREATMENT OF TAUOPATHIES IN SCIENCE TRANSLATIONAL MEDICINE

Pinteon Therapeutics, a biotechnology company focused on protecting neuronal health by targeting neurotoxic forms of tau, is encouraged by the publication of a preclinical study supporting PNT001 for the treatment of vascular dementia and tauopathies in Science Translational Medicine.

The study, led by researchers at Beth Israel Deaconess Medical Center (BIDMC), a research affiliate of Harvard Medical School, showed that a monoclonal antibody targeting cis-pT231 reduced neurodegeneration and cognitive impairment in a mouse model of vascular dementia and in a model of human tau overexpression. Pinteon licensed its cis-pT231 tau antibody, PNT001, from the BIDMC team.

“This is an important preclinical study showing the ability of an antibody targeting cis-pT231 tau to improve cognitive function and reduce neurodegeneration in two mouse models,” said Michael Ahlijanian, Ph.D., Pinteon’s chief scientific officer. “As PNT001 is a humanized version of this antibody, we believe this study provides further evidence for the ability of PNT001 to treat the cognitive impairments seen in tauopathies like Alzheimer’s disease and other neurodegenerative disorders. We are excited by these findings as we look to begin a Phase 1b/Phase 2 study of PNT001 in patients with Alzheimer’s disease later this year.”

Pinteon recently announced promising Phase 1 data showing PNT001 was well-tolerated at dose levels that may provide potential therapeutic effect. In addition, it is conducting a Phase 1b multiple ascending dose study of PNT001 in patients with acute traumatic brain injury. The company expects to initiate a Phase 1b/Phase 2 study of PNT001 in patients with Alzheimer’s disease by the end of 2021.

About Pinteon Therapeutics

Pinteon Therapeutics is advancing clinical studies of a novel antibody that aims to interrupt the spread of toxic tau and protect and preserve brain function in patients with neurodegenerative disease, with a focus on Alzheimer’s disease and traumatic brain injury. Pinteon’s lead asset, PNT001, is the only antibody in development that targets cis-pT231 tau, a neurotoxic epitope that has been identified in multiple preclinical studies as a potent driver of neurodegenerative disease. The company reported promising Phase 1 safety data early in 2021 showing PNT001 was well-tolerated at dose levels that may provide potential therapeutic effect. Pinteon is led by an experienced management team with strong track records in CNS drug discovery and development and is funded by Morningside Ventures. For more information, visit pinteon.com.

Contacts

Stephanie Simon

Ten Bridge Communications

[email protected]
617-581-9333